iifl-logo-icon 1

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Lupin announces launch of Formoterol Fumarate Inhalation Solution in the US; stock jumps ~2%

29 Nov 2022 , 12:23 PM

Lupin Limited today announced the launch of Formoterol Fumarate Inhalation Solution, 20 mcg/2 mL per Unit-Dose Vial, as a generic equivalent to Mylan Specialty, L.P.’s Perforomist Inhalation Solution, 20 mcg/2 mL.

In the United States, Formoterol Fumarate Inhalation Solution (RLD Perforomist) had an estimated annual sales of USD 268 million, as per the IQVIA MAT September 2022.

Lupin is a Mumbai-based transnational pharmaceutical company in India that focuses on innovation. The Company develops and commercialises a diverse range of branded and generic formulations, biotechnology products, and APIs in over 100 markets worldwide, including the United States, India, Asia Pacific (APAC), South Africa, Latin America (LATAM), Europe, and the Middle East.

At around 12.20 PM, Lupin was trading at Rs745.80 up by Rs12.1 or 1.65% from its previous closing of Rs733.70 on the BSE. The scrip touched intraday high and low of Rs759.15 and Rs740.25 respectively.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Lupin Launch
  • Lupin News
  • Lupin Stock
  • Lupin Updates
  • LupinChina
  • LupinPartnership
  • LupinShare
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.